Cargando…
PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2
BACKGROUND: In the last years, the transmembrane proteoglycan NG2 has gained interest as a therapeutic target for the treatment of diverse tumor types, including gliomas, because increases of its expression correlate with dismal prognosis. NG2 has been shown to function as a co-receptor for PDGF lig...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964636/ https://www.ncbi.nlm.nih.gov/pubmed/20939912 http://dx.doi.org/10.1186/1471-2407-10-550 |